Skip Navigation



Journal of the National Cancer Institute Advance Access published online on November 5, 2009
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djp400
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zohar, S.
Right arrow Articles by O'Quigley, J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zohar, S.
Right arrow Articles by O'Quigley, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved.

CORRESPONDENCE

Re: Dose Escalation Methods in Phase I Cancer Clinical Trials

Sarah Zohar, John O'Quigley

Affiliations of authors: Inserm UMRS 717, Hôpital Saint-Louis, Paris, France (SZ); Inserm, University Paris VI, Paris, France (JO)

Correspondence to: Sarah Zohar, PhD, Inserm UMRS 717, Hôpital Saint-Louis, 1 Ave Calude Vellefaux, Paris, France 75010 (e-mail: sarah.zohar@sls.aphp.fr).

The first 10% of the full text of this article appears below.

The review by Le Tourneau et al. (1) missed some important references that contradict a number of their main findings. For example, they found that the widely used standard 3 + 3 design is simple to implement and safe. It is simple, no argument. However, several studies (2–6) . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?